Crohn Disease
CD19+ in intestinal mucosa may predict response to infliximab
Published in Immunotherapy Weekly, August 31st, 2005
"Infliximab is an effective treatment for Crohn's disease, yet about 30% of patients have a weak or no response. The aim of the study was to determine if the likelihood of a patient achieving complete remission 3 months after treatment with infliximab can be predicted from immunological parameters measured in peripheral blood and inflamed intestinal mucosa before the treatment. Twenty-five patients with Crohn's disease resistant to conventional therapy underwent treatment with infliximab," scientists writing in the journal Hepato-Gastroenterology reported.
"Samples...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2005-08-31)
More Articles from Immunotherapy Weekly
- Allergy Medicine
Oral tolerance in absence of naturally occurring Tregs examined - Asthma
Exhaled nitric oxide not useful as diagnostic marker during acute attacks - Cancer Immunotherapy
Genetic investigations reveal unique tumor antigens - Graft-versus-Host Disease
Chronic graft-versus-host disease modeled, nephrin autoantibodies implicated - Adenovirus Vector
Capsid modifications enable flexible targeting of adenovirus vectors - Allergy & Immunology
Activation of innate immune system has role in chemically induced autoimmunity - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
